We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 314.00
Bid: 312.00
Ask: 314.00
Change: 24.00 (8.28%)
Spread: 2.00 (0.641%)
Open: 310.00
High: 314.00
Low: 310.00
Prev. Close: 290.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

NOTIFICATION OF MAJOR HOLDINGS

1 Nov 2017 09:45

RNS Number : 2399V
Hutchison China Meditech Limited
01 November 2017
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Hutchison China MediTech Limited;

Legal Entity Identifier: 2138006X34YDQ6OBYE79

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

X

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii: Voluntary disclosure

X

3. Details of person subject to the notification obligationiv

Name

Hutchison Healthcare Holdings Limited

City and country of registered office (if applicable)

British Virgin Islands

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

30/10/2017

6. Date on which issuer notified (DD/MM/YYYY):

30/10/2017

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

60.36%

60.36%

66,435,037

Position of previous notification (if

applicable)

60.36%

60.36%

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary Shares (KYG4672N1016) and American Depositary Shares (US44842L1035)

40,097,877

60.36%

SUBTOTAL 8. A

40,097,877

60.36%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

CK Hutchison Holdings Limited - indirect, but ultimate, owner of the shareholder

60.36%

60.36%

Hutchison Whampoa (China) Limited - direct owner of the shareholder and a subsidiary of CK Hutchison Holdings Limited

60.36%

60.36%

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

Voluntary notification following an offering of American Depository Shares by Hutchison China MediTech Limited.

 

Place of completion

Hong Kong

Date of completion

31 October 2017

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLBBBLTMBJMMFR
Date   Source Headline
12th May 20231:15 pmRNSAnnual General Meeting Poll Results
12th May 20239:30 amRNSBoard of Directors and Board Committee Membership
10th May 20239:30 amRNSAppointment of Independent NED
28th Apr 20239:30 amRNSTotal Voting Rights
21st Apr 20239:30 amRNSVesting of awards under the LTIP
18th Apr 20237:00 amRNSNDA Acceptance in China for Fruquintinib
12th Apr 20237:00 amRNSPresentations at AACR Annual Meeting 2023
11th Apr 20239:30 amRNSIntended Retirement of Independent NED
11th Apr 20239:30 amRNS2022 Annual Report and Notice of AGM
4th Apr 202310:30 amRNSHUTCHMED Initiates Registration Phase Enrollments
31st Mar 20239:30 amRNSTotal Voting Rights
31st Mar 20237:00 amRNSRolling Submission of Fruquintinib US NDA Complete
14th Mar 20231:30 pmRNSClosing of Fruquintinib License to Takeda
8th Mar 20238:30 amRNSDirector's Share Dealing
6th Mar 20238:30 amRNSVesting of awards under the LTIP
28th Feb 202312:15 pmRNSPublication of Form 20-F
28th Feb 20238:30 amRNS2022 Full Year Results and Business Updates
27th Feb 202310:00 amRNSEnrollment Completed in Phase 2 Amdizalisib trial
31st Jan 20238:30 amRNSNotice of Results
23rd Jan 20238:00 amRNSLicense to Takeda for Fruquintinib outside China
18th Jan 20232:30 pmRNSInclusion of ORPATHYS in NRDL in China
3rd Jan 20238:30 amRNSEnrollment Completed in Phase 3 Trial
30th Dec 20228:30 amRNSBlocklisting Six Monthly Return
19th Dec 202210:00 amRNSFDA NDA Rolling Submission for Fruquintinib
15th Nov 20227:00 amRNSHUTCHMED Announces Strategy Update
14th Nov 20227:00 amRNSPositive Topline Phase 3 Result in Fruquintinib
27th Oct 202212:30 pmRNSHUTCHMED Initiates Phase 2/3 Trial of Fruquintinib
21st Oct 20229:30 amRNSVesting of awards under the LTIP
10th Oct 20229:30 amRNSPhase II/III Trial of Sovleplenib for in China
30th Sep 20229:30 amRNSTotal Voting Rights
14th Sep 202211:00 amRNSShare Option Scheme and Long Term Incentive Plan
8th Sep 20227:00 amRNSFRESCO-2 Colorectal Cancer MRCT Data Highlights
23rd Aug 202210:00 amRNSHolding(s) in Company
23rd Aug 20229:30 amRNSHUTCHMED To Present FRESCO-2 Data at ESMO 2022
9th Aug 20229:30 amRNSFirst Participant in Phase I Trial of IMG-004
8th Aug 20229:30 amRNSPreliminary results from SAVANNAH Phase 2 Trial
8th Aug 20227:00 amRNSFRESCO-2 Study Has Met Primary Endpoint
1st Aug 202212:04 pmRNSInterim Results and Business Updates
1st Aug 20227:00 amRNSHUTCHMED Initiates Bridging Study of Tazemetostat
15th Jul 20229:30 amRNSHUTCHMED Initiates Phase I Trial of HMPL-A83
13th Jul 20227:00 amRNSResults of SAVANNAH Global Phase II Trial at WCLC
6th Jul 20227:00 amRNSFirst Participants in Phase I Trial of IMG-007
30th Jun 20229:30 amRNSTotal Voting Rights
29th Jun 20229:30 amRNSBlocklisting Six Monthly Return
27th Jun 20229:30 amRNSHUTCHMED to Announce 2022 Half-Year Results
1st Jun 20229:30 amRNSTAZVERIK® Approved in Hainan Pilot Zone
24th May 202211:00 amRNSLTIP and Share Options
16th May 202212:00 pmRNSAppointment of Non–Executive Director
3rd May 20227:00 amRNSHUTCHMED Receives CRL from the US FDA
27th Apr 20222:30 pmRNSAnnual General Meeting Poll Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.